April 29th 2024
I reflected upon my last great trip with my husband and the moment my wait and watch approach ended for my follicular lymphoma.
FDA Approves Tazverik for Certain Patients With Relapsed/Refractory Follicular Lymphoma
June 18th 2020The Food and Drug Administration approved Tazverik for adults with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation and have received treatment with at least two systemic therapies, as well as patients who have no other treatment options.